ATE388722T1 - THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS - Google Patents

THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS

Info

Publication number
ATE388722T1
ATE388722T1 AT96918137T AT96918137T ATE388722T1 AT E388722 T1 ATE388722 T1 AT E388722T1 AT 96918137 T AT96918137 T AT 96918137T AT 96918137 T AT96918137 T AT 96918137T AT E388722 T1 ATE388722 T1 AT E388722T1
Authority
AT
Austria
Prior art keywords
fragment
solution
vwf
denaturant
aqueous solution
Prior art date
Application number
AT96918137T
Other languages
English (en)
Inventor
David L Farb
Michael E Hrinda
Ted C K Lee
Christopher P Prior
David Weber
Original Assignee
Aventis Behring L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring L L C filed Critical Aventis Behring L L C
Application granted granted Critical
Publication of ATE388722T1 publication Critical patent/ATE388722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96918137T 1995-06-07 1996-06-06 THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS ATE388722T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,445 US5847086A (en) 1991-06-20 1995-06-07 Therapeutic fragments of von Willebrand factor

Publications (1)

Publication Number Publication Date
ATE388722T1 true ATE388722T1 (de) 2008-03-15

Family

ID=23935756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918137T ATE388722T1 (de) 1995-06-07 1996-06-06 THERAPEUTISCHE FRAGMENTE DES ßVON WILLEBRANDß FAKTORS

Country Status (11)

Country Link
US (1) US5847086A (de)
EP (1) EP0833659B1 (de)
JP (1) JP4233114B2 (de)
KR (1) KR100486472B1 (de)
AT (1) ATE388722T1 (de)
AU (1) AU716449B2 (de)
CA (1) CA2223702C (de)
DE (1) DE69637464T2 (de)
ES (1) ES2302336T3 (de)
MX (1) MX9709893A (de)
WO (1) WO1997018834A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905886B2 (en) * 2000-08-11 2005-06-14 Quest Diagnostics Investments Incorporated Preservative solutions
US6387711B1 (en) * 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
WO2003059291A2 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US20080160024A1 (en) * 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
SG11202012933QA (en) * 2018-06-29 2021-01-28 Ribomic Inc Aptamer preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
ES2070116T3 (es) * 1986-05-30 1995-06-01 Scripps Research Inst Peptidos que inhiben la union del factor von willebrand.
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins
WO1992017192A1 (en) * 1991-03-27 1992-10-15 The Scripps Research Institute Therapeutic fragments of von willebrand factor
ES2233924T3 (es) * 1991-06-20 2005-06-16 Aventis Behring L.L.C. Un procedimiento para preparar fragmentos terapeuticos de factor von willebrand.
DE69333928T2 (de) * 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
US5827773A (en) * 1997-03-07 1998-10-27 Sharp Microelectronics Technology, Inc. Method for forming polycrystalline silicon from the crystallization of microcrystalline silicon

Also Published As

Publication number Publication date
DE69637464T2 (de) 2008-11-06
WO1997018834A1 (en) 1997-05-29
KR19990022634A (ko) 1999-03-25
AU6047196A (en) 1997-06-11
US5847086A (en) 1998-12-08
ES2302336T3 (es) 2008-07-01
CA2223702A1 (en) 1997-05-29
MX9709893A (es) 1998-08-30
JP4233114B2 (ja) 2009-03-04
DE69637464D1 (de) 2008-04-24
AU716449B2 (en) 2000-02-24
JP2001517197A (ja) 2001-10-02
EP0833659B1 (de) 2008-03-12
CA2223702C (en) 2008-07-29
EP0833659A1 (de) 1998-04-08
EP0833659A4 (de) 2003-01-15
KR100486472B1 (ko) 2005-09-02

Similar Documents

Publication Publication Date Title
Stenflo et al. Vitamin K and the biosynthesis of prothrombin: I. Identification and purification of a dicoumarol-induced abnormal prothrombin from bovine plasma
DE69637464D1 (de) Therapeutische fragmente des "von willebrand" faktors
KR900701823A (ko) 혈장단백질의 크로마토그래피 분리법
KR850004593A (ko) 인자 ⅷ:c의 정제방법
ATE251668T1 (de) Reinigung von plasmafraktion
AU591397B2 (en) Method of preparing alpha-1-proteinase inhibitor
ATE187462T1 (de) Reinigung von alpha-l-proteinaseinhibitor mittels neuen chromatographischen trennungsbedingungen
CA1208130A (en) ULTRAPURIFICATION OF FACTOR VIII
ATE275343T1 (de) Verarbeitung von pflantzlichem material mit xylanase
EP0239565A3 (en) Method of and apparatus for separating proteins
ITFI920078A1 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
AU2253392A (en) Therapeutic fragments of von willebrand factor
KR930023371A (ko) 사람의 뇨로부터의 유용 단백질의 생산방법
MY119366A (en) A process for the preparation of factor ix from biological sources
DE69117956D1 (de) Reinigung von erwinia-l-asparaginase
DE69303941D1 (de) Verfahren zur Herstellung von hochreinem Fibrinogen
ZA966315B (en) Method for the purification of proteins
EP0085220A3 (de) Verfahren zur Reinigung des Hormons der vorderen Hypophyse
KR890008167A (ko) 인자 viii의 정제에 사용하기 위한 펩타이드 및 그 제조방법
Ninfali et al. Goat immunoglobulin purification on phosphocellulose and DEAE Affi-Gel blue
SE9303822D0 (sv) Method for purification
HUT35289A (en) Immune interferon and process for its purification
KR940005284A (ko) 면역친화성 크로마토그래피에 의한 플라스미노겐 활성화제 억제제 2의 정제방법
IT9019132A1 (it) Assorbenti tiofilici
GB2091739A (en) Purification of Human Growth Hormone

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833659

Country of ref document: EP

EEFA Change of the company name